RSV Drives Rise in Severe Respiratory Illness Across Brazil; Vaccine Protection Lasts Up to Three Years

Brazil is experiencing an increase in severe acute respiratory syndrome (SRAG) cases, primarily driven by the heightened circulation of the respiratory syncytial virus (RSV), according to Fiocruz's InfoGripe bulletin. While RSV leads in respiratory infection cases, influenza is responsible for the majority of deaths. RSV is a significant cause of bronchiolitis and pneumonia in children under two years old, accounting for approximately 75% of bronchiolitis cases and 40% of pneumonia cases. Beyond infants, adults and elderly individuals with chronic conditions such as asthma, COPD, cardiovascular diseases, and diabetes are also highly susceptible to RSV. For high-risk adults, a private sector vaccine offers protection for at least three years. The impact is already evident in healthcare systems, with Porto Alegre seeing nearly a 20% rise in medical consultations within a single month, exceeding 33,000 expected visits. RSV cases are escalating across the South, parts of the Southeast, and some states in the North, Northeast, and Center-West regions, underscoring concerns about respiratory virus activity during autumn and winter. The SUS offers RSV vaccination for pregnant individuals from the 28th week of gestation to protect newborns through maternal antibody transfer. Premature infants and those with comorbidities can also receive nirsevimabe for enhanced RSV protection. Private clinics offer two RSV vaccines for adults, recommended for the elderly and individuals over 18 with comorbidities, particularly lung and heart conditions. One of these vaccines, enhanced with an adjuvant, provides protection for at least three years, a notable duration compared to the shorter protection offered by flu and COVID-19 vaccines. Natural RSV infection does not confer permanent immunity, and reinfections are common, making vaccination advisable for eligible individuals even after prior infection. Although RSV is widely known for its risk to infants, it can also cause severe illness in vulnerable adults, including the elderly (over 65), individuals with COPD, and heart disease patients, potentially leading to severe pneumonia, hospitalization, ICU admission, mechanical ventilation, and death. Symptoms of RSV can mimic those of influenza, such as sore throat, cough, runny nose, body aches, and fever, making laboratory testing necessary for accurate diagnosis and appropriate treatment, especially for influenza where antivirals like oseltamivir are available, unlike for RSV. Simple preventive measures like staying home when symptomatic, wearing masks, hand hygiene, and avoiding visits to vulnerable individuals during illness outbreaks remain crucial in reducing transmission.